Approval · Notice of Compliance 11131 · 2010
REQUIP: Notice of Compliance 11131
Issued March 11, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11131
- Date
- March 11, 2010
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Dosage recommendation in patients with end stage renal disease (ESRD) who are receiving regular haemodialysis
- Therapeutic class
- Antiparkinsonian agent / Dopamine agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REQUIP | Not yet assigned | — |
Medicinal ingredients
- ROPINIROLE HYDROCHLORIDE 0.25 MG per TAB
- ROPINIROLE HYDROCHLORIDE 0.5 MG per TAB
- ROPINIROLE HYDROCHLORIDE 1 MG per TAB
- ROPINIROLE HYDROCHLORIDE 2 MG per TAB
- ROPINIROLE HYDROCHLORIDE 3 MG per TAB
- ROPINIROLE HYDROCHLORIDE 4 MG per TAB
- ROPINIROLE HYDROCHLORIDE 5 MG per TAB